At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Carfilzomib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Phase I/II Study of Carfilzomib, Ruxolitinib, and Low Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Carfilzomib, Ruxolitinib, and 1 other intervention for Multiple Myeloma. Completed, enrolled 12 participants across 2 sites.
Detailed Summary
The primary objective of Phase I is to establish the maximum tolerated dose (MTD) of ruxolitinib in combination with carfilzomib and dexamethasone. The primary objective of phase II is to evaluate progression-free survival (PFS) at 4 months in multiple myeloma subjects who receive the combination treatment carfilzomib, dexamethasone, and ruxolitinib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsIncyte Corporation, Multiple Myeloma Research Consortium, Amgen
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartJan 2019
Primary CompletionNov 2022
Study CompletionFeb 2024
TodayJul 2026
First PostedDec 12, 2018
Enrollment StartJan 3, 2019
Primary CompletionNov 7, 2022
Study CompletionFeb 21, 2024
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 7.6 years ago
Interventions
Carfilzomibdrug
Irreversible proteasome inhibitor
Ruxolitinibdrug
Oral JAK inhibitor
Dexamethasonedrug
glucocorticoid